Internal Medicine, Rheumatology · Woodland Hills, CA
NPI
1447437967
Since 2008
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
23067 Ventura Blvd Ste 200
Woodland Hills, CA, 91364
Phone (818) 598-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
78,371 services
Medicare patients, 2024
496
Average age 73
Drug cost, 2024
$5.0M
1,576 prescriptions
Company payments, 2025
$10K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nazanin Firooz was code J3111 (injection, romosozumab-aqqg, 1 mg), 14,490 times for 16 patients. In total Nazanin Firooz billed 78,371 services in 78 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 14,490 | 16 | $8.59 | $125K |
| J3490 Unclassified drugs | Office | 10,600 | 61 | $0.05 | $480 |
| J0897 Injection, denosumab, 1 mg | Office | 7,080 | 73 | $20.57 | $146K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 3,830 | 19 | $25.01 | $96K |
| 99214 Office E&M - Established | Office | 1,006 | 335 | $105.98 | $107K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 756 | 63 | $0.21 | $162 |
| 96375 Injection Administration | Office | 636 | 120 | $13.51 | $8,595 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 632 | 109 | $0.50 | $318 |
| 96360 Intravenous Infusion, Hydration | Office | 586 | 116 | $29.11 | $17K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 478 | 107 | $53.18 | $25K |
| 96365 Intravenous Infusion, Hydration | Office | 384 | 72 | $55.50 | $21K |
| 96401 Chemotherapy Administration | Office | 367 | 118 | $64.49 | $24K |
| 96372 Injection Administration | Office | 364 | 61 | $12.11 | $4,409 |
| G3002 Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan tha | Office | 314 | 187 | $67.46 | $21K |
| 96413 Chemotherapy Administration | Office | 314 | 70 | $118.42 | $37K |
By year: 2022 $892K for 58,323 services; 2023 $1.4M for 60,990 services; 2024 $1.2M for 78,371 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 252 | 36 | $17.57 | $4,428 |
| 36415 Venipuncture Blood Collection | 147 | 58 | $8.59 | $1,263 |
| 83516 Immunoassay | 79 | 40 | $11.30 | $893 |
| 86431 Immunoassay | 39 | 39 | $5.56 | $217 |
| 86200 Immunoassay | 39 | 39 | $12.69 | $495 |
| 86225 Immunoassay | 36 | 36 | $13.47 | $485 |
| 86226 Immunoassay | 35 | 35 | $11.87 | $415 |
| 86038 Immunoassay | 29 | 29 | $11.85 | $344 |
| 86376 Immunoassay | 27 | 27 | $14.26 | $385 |
Medicare prescription drug claims, 2024
In 2024, the drug Nazanin Firooz prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 131 prescriptions and refills. In total Nazanin Firooz wrote 1,576 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 131 | 221 | 50 | $4,299 |
| Prednisone Generic | 102 | 142 | 46 | $564 |
| Methotrexate Methotrexate Sodium | 86 | 159 | 26 | $1,997 |
| Evenity (2 Syringes) Romosozumab-Aqqg | 74 | 74 | 13 | $179K |
| Orencia Abatacept/Maltose | 69 | 73 | Under 11 | $338K |
| Actemra Tocilizumab | 68 | 72 | Under 11 | $254K |
| Prolia Denosumab | 61 | 363 | 42 | $105K |
| Cimzia (2 Pack) Certolizumab Pegol | 51 | 73 | Under 11 | $436K |
| Rinvoq Upadacitinib | 47 | 55 | Under 11 | $347K |
| Duloxetine Hcl Generic | 40 | 61 | 11 | $801 |
| Remicade Infliximab | 38 | 44 | Under 11 | $163K |
| Benlysta Belimumab | 36 | 36 | Under 11 | $146K |
| Gabapentin Generic | 29 | 53 | 13 | $269 |
| Celecoxib Generic | 27 | 34 | Under 11 | $1,769 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 26 | 26 | Under 11 | $193K |
Brand drugs: - claims; generic drugs: 826 claims; opioid claims: 34.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nazanin Firooz $10K ($10K in general payments such as food, travel and fees) from 18 companies. The largest payer was Novartis Pharmaceuticals Corporation with $7,370.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 41 | $7,370 |
| Abbvie Inc. ABBV | 30 | $754 |
| Amgen Inc. AMGN | 35 | $653 |
| GlaxoSmithKline, LLC. GSK | 13 | $258 |
| Mallinckrodt Hospital Products Inc. | 9 | $224 |
| Janssen Biotech, Inc. JNJ | 10 | $207 |
| UCB, Inc. UCB.BR | 8 | $207 |
| Alexion Pharmaceuticals, Inc. AZN | 7 | $164 |
| Radius Health, Inc. | 5 | $118 |
| Octapharma USA, Inc. | 3 | $95.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.